Results 81 to 90 of about 7,028 (198)

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks

Frontiers in Immunology
BackgroundAtopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced by cytokines dependent on Janus kinases (JAKs).
Teppei Hagino, Risa Hamada, Mai Yoshida, Eita Fujimoto, Hidehisa Saeki, Naoko Kanda   +5 more
doaj   +1 more source

Phenotypes and clinical outcomes in children with moderate‐to‐severe atopic dermatitis across diverse ancestries: a Spanish multicenter observational study and cluster analysis (AD‐SKINS Project)

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Atopic dermatitis (AD) has a highly variable clinical phenotype and ancestry can contribute to this heterogeneity. This study aims to identify clinical phenotypes of AD in children from diverse ancestry groups, evaluate clinical outcomes and response to treatment, and define phenotypic clusters with potential relevance.
Eugeni Prat‐Colilles, Adrià Plana‐Pla, Asunción Vicente, Eulàlia Baselga, Helena Iznardo, Esther Roé, Miquel Casals‐Andreu, Maria Sin‐Soler, Josep A. Pujol‐Montcusí, Maria del Mar Cordellat‐Martínez, Xavier Soria‐Gili, Maria del Mar Tapias‐Terré, Marta Bertolin‐Colilla, Nidia Planella‐Fontanillas, Laura Marques‐Martín, Mónica Munera‐Campos, Maria Fabregat‐Pratdepadua, Carolina S. Prat‐Torres, Marta Ivars, Luisa F. Montenegro‐Morillo, Isabel Bielsa‐Marsol, Jose‐Manuel Carrascosa‐Carrillo   +21 more
wiley   +1 more source

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Research & Therapy
Background In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel   +13 more
doaj   +1 more source

Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Oral lichen planus (OLP) is a chronic autoimmune mucosal disease with malignant potential and limited treatment options. This study evaluated the long‐term efficacy and safety of cold atmospheric plasma (CAP) therapy in therapy‐refractory OLP and introduced the novel Lichen Planus Severity Score (LPSS).
Christian Seebauer, Hans‐Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein   +5 more
wiley   +1 more source

Erosion Regression in Patients with RA After Upadacitinib-A Pilot Study Using High Resolution Peripheral Quantitative Computed Tomography

Journal of Clinical Rheumatology and Immunology
Background: Janus kinases inhibitor (JAKi) is a potent drug in treating patients with rheumatoid arthritis (RA). However, the effect of JAKi on finite structural changes remained uncertain.
Isaac T Cheng, Ho So, Evelyn H Chow, Qihan Wu, Martin Li, Vivian W Hung, Ling Qin, Chun Kwok Wong, Lai Shan Tam   +8 more
doaj   +1 more source

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2023
Wenting Hu, Si Zhang, Cuihong Lian Department of Dermatology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Cuihong Lian, Department of Dermatology, Shenzhen Second People’s Hospital, No.
Hu W, Zhang S, Lian C
doaj  

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study [PDF]

INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response ...
Allegretti, Jessica R., Cabral, Heidy J., Kallumkal, Govind, Dalal, Rahul S., Barnes, Edward L.   +4 more
core   +2 more sources

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

International Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller, Helmut Beltraminelli, Wolf‐Henning Boehncke, Maximilian Böhm, Antonio Cozzio, Peter Häusermann, Ahmad Jalili, Antonios G. A. Kolios, Claudia Lang, Eva Loos, Christoph Schlapbach, Curdin Conrad   +11 more
wiley   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source